...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Prostate >Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.
【24h】

Chromogranin A and B and secretogranin II in prostatic adenocarcinomas: neuroendocrine expression in patients untreated and treated with androgen deprivation therapy.

机译：前列腺腺癌中的嗜铬粒蛋白A和B和分泌素粒II：未经雄激素剥夺治疗和未接受雄激素剥夺治疗的患者的神经内分泌表达。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Neuroendocrine (NE) expression in prostatic adenocarcinomas (PACs) has been related to an adverse clinical course, but the reported data are not unequivocal. METHODS: We immunostained a series of 64 PACs with three monoclonal antibodies raised against chromogranin A (CgA), chromogranin B (CgB), and secretogranin II (SgII). The patients were followed up for 18-88 months (mean 43 months, standard deviation +/- 20 months); 58 of them received preoperative androgen deprivation therapy for 3-6 months. RESULTS: Of the 64 PACs under study, 39 (approximately 61%) were immunoreactive to CgA, 51 (approximately 80%) to CgB, and 38 (approximately 59%) to SgII. We found a strict correlation between pronounced neuroendocrine differentiation and the most poorly differentiated tumors (P = 0.01 for CgA, P = 0.03 for CgB, and P = 0.05 for SgII), and relationship (approaching statistical significance only for CgB, P = 0.07) between Cgs/Sg expression and advanced (C and D) clinical stage. However, we failed to detect any correlation between chromogranin expression and clinical outcome. CONCLUSIONS: These results suggest that NE differentiation is a frequent event in PACs, especially in the most poorly differentiated. Nevertheless, as Cgs/Sg expression is not clearly related to advanced clinical stage and poor prognosis, our findings suggest that clinical staging and grading, rather than NE differentiation, remain the most powerful prognostic indicators in PACs.
机译：背景：前列腺腺癌（PACs）中神经内分泌（NE）的表达与不良的临床病程有关，但报道的数据并非明确。方法：我们用三种针对嗜铬粒蛋白A（CgA），嗜铬粒蛋白B（CgB）和促胰泌素II（SgII）的单克隆抗体对64个PAC进行了免疫染色。随访18-88个月（平均43个月，标准差+/- 20个月）。其中58例接受了3-6个月的术前雄激素剥夺治疗。结果：在研究的64个PAC中，有39个（约61％）对CgA免疫反应，对CgB有51个（约80％），对SgII有38个（约59％）。我们发现明显的神经内分泌分化与分化最差的肿瘤之间密切相关（CgA为P = 0.01，CgB为P = 0.03，SgII为P = 0.05）和关系（仅对CgB具有统计学意义，P = 0.07） Cgs / Sg表达与晚期（C和D）临床阶段之间的关系。但是，我们未能检测到嗜铬粒蛋白表达与临床结果之间的任何相关性。结论：这些结果表明NE分化是PAC中的常见事件，尤其是在分化最差的地区。然而，由于Cgs / Sg的表达与临床晚期和预后不良没有明显关系，因此我们的研究结果表明，临床分期和分级（而非NE分化）仍然是PACs中最有力的预后指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号